No, Repatha Is Not a Statin
Repatha (evolocumab) is a PCSK9 inhibitor, a biologic drug that lowers LDL cholesterol by blocking the PCSK9 protein, which helps the liver remove more LDL from the blood.[1] Statins, by contrast, are small-molecule drugs like atorvastatin (Lipitor) or rosuvastatin (Crestor) that primarily inhibit HMG-CoA reductase, an enzyme in cholesterol production.[2]
How Repatha Differs from Statins in Treatment
Repatha targets a different pathway, making it effective for patients who don't tolerate statins or need extra LDL reduction alongside them. Clinical trials show it cuts LDL by 50-70% on top of statins, reducing cardiovascular events by about 20% in high-risk groups.[3] Statins alone typically lower LDL by 20-60%, depending on dose and type.
When Doctors Prescribe Repatha Over Statins
Physicians use Repatha for familial hypercholesterolemia, atherosclerotic cardiovascular disease, or statin intolerance (affecting up to 10-15% of patients due to muscle pain).[4] It's not first-line; guidelines recommend maximizing statins first, then adding PCSK9 inhibitors like Repatha if LDL stays above 70 mg/dL.
Common Side Effects Compared to Statins
Repatha causes injection-site reactions (5-10%), flu-like symptoms, or rare allergic responses, with low muscle-related issues.[1] Statins more often lead to muscle aches (5-30%), liver enzyme elevations, or new-onset diabetes risk (about 9% relative increase).[2] Both are generally safe long-term.
Who Makes Repatha and Patent Status
Amgen manufactures Repatha, approved by the FDA in 2015. Key patents expire around 2030-2034 in the US, with biosimilar challenges possible earlier via litigation; check DrugPatentWatch.com for updates on extensions or disputes.[5]
[1] Repatha prescribing information, Amgen. https://www.repatha.com
[2] StatPearls, NCBI: Statins. https://www.ncbi.nlm.nih.gov/books/NBK430940/
[3] FOURIER trial, NEJM 2017. https://www.nejm.org/doi/full/10.1056/NEJMoa1706445
[4] AHA/ACC Cholesterol Guidelines, 2018. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000625
[5] DrugPatentWatch: Evolocumab patents. https://www.drugpatentwatch.com/p/tradename/REPATHA